References
Niederhuber JE, Armitage JO, Doroshow JH, Kastan MB, Tepper JE. Abeloff's clinical oncology. 5th ed. Philadelphia: Elsevier; 2014. p. 1373–96.
Eckel F, Brunner T, Jelic S. Biliary cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of Oncology. 2016;27(supplement 5):v28–37. https://doi.org/10.1093/annonc/mdw324.
NCCN Guidelines hepatobiliary cancers, version 2.2016.
Sheth S, Bedford A, Chopra S. Primary gallbladder cancer: recognition of risk factors and the role of prophylactic cholecystectomy. Am J Gastroenterol. 2000;95(6):1402–10. https://doi.org/10.1111/j.1572-0241.2000.02070.x.
Shrikhande SV, Barreto SG, Singh S, Udwadia TE, Agarwal AK. Cholelithiasis in gallbladder cancer: coincidence, cofactor, or cause. Eur J Surg Oncol. 2010;36(6):514–9. https://doi.org/10.1016/j.ejso.2010.05.002.
Hundal R, Shaffer EA. Gallbladder cancer: epidemiology and outcome. Clin Epidemiol. 2014;6:99–109. https://doi.org/10.2147/CLEP.S37357.
Eckel F, Schmid RM. Chemotherapy in advanced biliary tract carcinoma: a pooled analysis of clinical trials. Br J Cancer. 2007;96(6):896–902. https://doi.org/10.1038/sj.bjc.6603648.
Valle J, Wasan H, Palmer DH, Cunningham D, Anthoney A, Maraveyas A, et al. ABC-02 trial investigators cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N Engl J Med. 2010;362(14):1273–81. https://doi.org/10.1056/NEJMoa0908721.
Yang R, Wang B, Chen YJ, et al. Efficacy of gemcitabine plus platinum agents for biliary tract cancers: a metanalysis. Anti-Cancer Drugs. 2013;24(8):871–7. https://doi.org/10.1097/CAD.0b013e3283637292.
Cho JY, Paik YH, Chang YS. Capecitabine combined with gemcitabine (CapGem) as first-line treatment in patients with advanced/metastatic biliary tract carcinoma. Cancer. 2005;104(12):2753–8. https://doi.org/10.1002/cncr.21591.
Knox J, Hedley D, Oza A, et al. Combining gemcitabine and capecitabine in patients with advanced biliary cancer: a phase II trial. JCO. 2005;23(10):2332–8. https://doi.org/10.1200/JCO.2005.51.008.
Riechelmann RP, Townsley CA, Chin SN, Pond GR, Knox JJ. Expanded phase II trial of gemcitabine and capecitabine for advanced biliary cancer. Cancer. 2007;110(6):1307–12. https://doi.org/10.1002/cncr.22902.
Iqbal S, Rankin C, Lenz H, et al. A phase II trial of gemcitabine and capecitabine in patients with unressectable or metastatic gallbladder cancer or cholangiocarcinoma: Southwest Oncology Group Study S0202. Cancer Chemother Pharmacol. 2011;68(6):1595–602. https://doi.org/10.1007/s00280-011-1657-1.
Fiteni F, Nguyen T, Vernerey D, Paillard M, et al. Cisplatin/gemcitabine or oxaliplatin/gemcitabine in the treatment of advanced biliary tract cancer: a systematic review. Cancer Med. 2014;3(6):1502–11. https://doi.org/10.1002/cam4.299.
Nishio H, Nagino M, Ebata T, Yokoyama Y, Igami T, Nimura Y. Aggressive surgery for stage IV gallbladder carcinoma; what are the contraindications? J Hepato-Biliary-Pancreat Surg. 2007;14(4):351–7. https://doi.org/10.1007/s00534-006-1187-0.
Kang MJ, Song Y, Jang J, et al. Role of radical surgery in patients with stage IV gallbladder cancer. HPB. 2012;14(12):805–11. https://doi.org/10.1111/j.1477-2574.2012.00544.x.
Creasy JM, Goldman DA, Dudeja V, Lowery MA, Cercek A, Balachandran VP, et al. Systemic chemotherapy combined with resection for locally advanced gallbladder carcinoma: surgical and survival outcomes. J Am Coll Surg. 2017;224(5):906–16. https://doi.org/10.1016/j.jamcollsurg.2016.12.058.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of Interest
The authors declare that they have no conflict of interest.
Rights and permissions
About this article
Cite this article
Castelo Branco, M., Estevinho, F., Correia Pinto, J. et al. Gallbladder Cancer: Complete Resection after Second Line Treatment in Stage IV Disease. J Gastrointest Canc 50, 564–567 (2019). https://doi.org/10.1007/s12029-017-0044-5
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12029-017-0044-5